Physician profile
Mikhail Shik
NPI 1891767000
$1,645.92
in general payments reported to CMS, 2019-2025
25 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $118 · 2021: $144 · 2022: $60.86 · 2023: $209 · 2024: $247 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $282.02 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Medtronic, INC. | $172.97 | 2021-2023 | Interstim, Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $170.39 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Amgen INC. | $128.06 | 2019-2024 | Krystexxa |
| Exactech, INC. | $114.33 | 2019 | |
| Pfizer INC. | $103.40 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $92.33 | 2019-2025 | Farxiga, Breztri |
| Allergan, INC. | $82.42 | 2019-2020 | |
| Glaxosmithkline, LLC. | $68.29 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $50.64 | 2023-2025 | Ubrelvy |
| Astellas Pharma US INC | $48.79 | 2019-2025 | Veozah |
| Abbott Laboratories | $37.98 | 2022 | |
| Phathom Pharmaceuticals, INC. | $36.48 | 2024 | Voquezna |
| Lilly USA, LLC | $34.85 | 2023-2025 | Mounjaro |
| Janssen Pharmaceuticals, INC | $33.13 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $28.37 | 2019 | |
| Lifescan, INC. | $22.88 | 2022 | |
| Ironshore Pharmaceuticals INC. | $22.22 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.14 | 2020 | |
| Amryt Pharma Holdings LTD | $18.54 | 2023 | Mycapssa |
| Verona Pharma, INC. | $17.78 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $17.17 | 2021 | |
| Ethicon US, LLC | $16.68 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.27 | 2023 | Xifaxan |
| Dynavax Technologies Corporation | $8.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Shik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.